| Background and significance:There is a bipolar causal relationship between comorbidity of diabetes and depression.Through rigorous and objective clinical efficacy evaluation,this project provides a more effective treatment plan for the clinical treatment of patients with type 2 diabetes and depression,delays the progression of the disease,and improves the quality of life of patients;Mechanism,Molecular cytoiogy level and cognitive assessment provide some reference value.Objective: To investigate the clinical effects and cognitive effects of minapuram in patients with type 2 diabetes mellitus and depression.Methods: 120 cases of Depression in Diabetes Mellitus in Shandong Daizhuang hospital from June 2018 to June 2020 were selected.They were randomly divided into experimental group and treatment group.The experimental group was given the clinical pathway of diabetes treatment,and Mina F Leon was given treatment at the same time.The control group was treated with esalapril,with oxalic acid,based on the clinical pathway of diabetes.After grouping treatment,the clinical indexes such as fasting blood glucose,serum total cholesterol and serum triglyceride were compared after 4,8 and 12 weeks.HAMD was used to evaluate the treatment effect of depression,LOTCA and WCST were used to evaluate the improvement of cognitive function,and Mars was used to evaluate the treatment compliance of patients.Result:1.General data test: There was no difference in age,gender,fasting blood glucose,serum total cholesterol and serum triglyceride between the two groups of patients(P>0.05).2.According to the comparative analysis of the data of the two groups,at the 4th,8th,and12 th weeks,there was no difference in FPG,TC,and TG of the patients(P>0.05).Secitalopram had no significant effect on the fasting blood glucose,serum total cholesterol and triacylglycerol levels of the patients,but the above indicators in the experimental group were controlled relatively well.There was no significant difference in the levels of FPG and TC at three time points in the experimental group compared with the control group at the same time(P>0.05).There was no statistical difference(P>0.05).3.The results showed that the HAMD scores of the experimental group at the 8th and12 th weekends of treatment were significantly different from those of the control group at the same period(P<0.05),but there was no significant difference in the HAMD scores at the 4th weekend of treatment(P>0.05).4.The LOTCA scores of the patients in the experimental group at three time points were significantly different from those in the control group at the same period(P<0.05),see Table 7 for details.After 12 weeks of group intervention,there were significant differences in the WCST indexes between the experimental group and the control group(P<0.05),and the cognitive function of the experimental group improved better.5.There were 50 cases(94.34%)in the experimental group with a total MARS score of≥6 points,and 38 cases(80.51%)in the control group with a total MARS score of ≥6points.There was a statistically significant difference between the two groups(=14.13,P<0.05).6.There were 5 patients in the experimental group that caused adverse events,accounting for 9.43%,of which 3 patients had drug side effects,accounting for 5.67%.Subsequent studies found that no more serious adverse drug events were found.In the control group,9 cases of adverse events were found in the study,accounting for 19.15%,and 40.64% of the events occurred because of drug side effects,only 5 cases.There were no serious events in the control group,so there was no significant difference in the safety of the two groups(P>0.05).Conclusions:1.The milnacipran group had more ideal control of fasting blood glucose,serum total cholesterol and serum triglyceride,which could improve the patient’s medication compliance.2.Both the milnacipran group and the escitalopram group can improve the individual cognitive function of patients with type 2 diabetes and depression,but the overall effective rate of milnacipran is higher,and the cognitive function of the patients is improved more obviously.Especially for patients with chronic physical diseases,the incidence of adverse events is low,and the treatment safety is high,which is worthy of clinical application. |
PDF Full Text Request